An Orthogonally Clickable and Stimuli-Responsive Poly(β-amino ester) for the Co-delivery of Doxorubicin and BCL-2 siRNA
Other authors
Publication date
2025-06-13ISSN
2637-6105
Abstract
A potent drug delivery system (DDS) based on poly(β-amino ester)s (pBAEs) to tackle multidrug resistance (MDR) in lung cancer by codelivering siRNA targeting antiapoptotic BCL-2 and doxorubicin (DOX) has been prepared. Engineered via strain-promoted azide–alkyne cycloaddition (SPAAC) to attach a tripeptide end-chain moiety and thiol–disulfide exchange to conjugate DOX, the system employs a hydrazone linker for dual pH- and redox-responsive release. This ensures precise tumor targeting with minimal leakage in the circulation. In multidrug-resistant lung cancer cells (GLC-4/ADR), it sharply downregulates BCL-2 expression, amplifying DOX’s therapeutic impact.
Document Type
Article
Document version
Published version
Language
English
Subject (CDU)
577 - Material bases of life. Biochemistry. Molecular biology. Biophysics
615 - Pharmacology. Therapeutics. Toxicology
616 - Pathology. Clinical medicine
Keywords
Pages
p.12
Publisher
American Chemical Society
Is part of
ACS Applied Polymer Materials 2025, 7 (11), 7013–7024
Grant agreement number
info:eu-repo/grantAgreement/SUR del DEC i FSE/FI/2019 FI_B01170
info:eu-repo/grantAgreement/SUR del DEC i FSE/FI/2020 FI_B1 00112
info:eu-repo/grantAgreement/SUR del DEC i FSE/FI/2021 FI_B2 00165
info:eu-repo/grantAgreement/MCI/PN I+D/PID2021-126346OB-I00
info:eu-repo/grantAgreement/SUR del DEC/SGR/SGR 2021 00537
This item appears in the following Collection(s)
Rights
© L'autor/a
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/4.0/